Published 4 years ago • loading... • Updated 4 years ago
U.S. FDA approves Amylyx ALS drug
Summary by Ground News
The FDA has approved an Amylyx Pharmaceuticals drug for amyotrophic lateral sclerosis (ALS) Relyvrio is a combination of two compounds, tauroursodeoxycholic acid and sodium phenylbutyrate, which together are intended to lead to longer survival of neurons. No serious adverse events were reported from the study.